Fidelity Investments
IMDX

Fidelity Investments’s Insight Molecular Diagnostics IMDX Stock Holding History

Fidelity Investments’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$15 – 5518
2025
Q2 		$15 Buy
+5
New +$15 ﹤0.01% 5278
2024
Q2 		– Sell
-13
Closed -$38 – 5560
2024
Q1 		$38 Buy
+13
New +$40 ﹤0.01% 5070
2023
Q3 		– Sell
-1
Closed -$2 – 5452
2023
Q2 		$2 Hold
1
– – ﹤0.01% 5340
2023
Q1 		$4 Hold
1
– – ﹤0.01% 5222
2022
Q4 		$3 Buy
+1
New +$11 ﹤0.01% 5311
2022
Q3 		– Sell
-304
Closed -$6K – 5249
2022
Q2 		$6K Buy
304
+171
+129% +$3.89K ﹤0.01% 4267
2022
Q1 		$4K Buy
+133
New +$4.25K ﹤0.01% 4503

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's IMDX Position: Q3 2025 in Review

Fidelity Investments sold out of Insight Molecular Diagnostics (IMDX) in Q3 2025, closing a stake of 5 shares — an estimated $15 sold.

Fidelity Investments first reported a position in IMDX in Q1 2022 and held it in 7 quarters. The position peaked at $6K in Q2 2022. 27 funds tracked by Wall St. Rank hold IMDX as of Q3 2025.

  • Fidelity Investments reported no remaining Insight Molecular Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 5 Insight Molecular Diagnostics shares in Q3 2025, an estimated $15.
  • Fidelity Investments first reported a position in Insight Molecular Diagnostics in Q1 2022 and held it in 7 quarters.
  • Fidelity Investments's Insight Molecular Diagnostics position peaked at $6K in Q2 2022.
  • 27 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.